Welcome

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The Company's pipeline currently includes product candidates for the treatment of cancer, thrombosis and atherosclerosis.

Meet us

- BioPharm America: Sep 15-17, 2010, Boston, MA, US
- European Cancer Cluster Partnering: Sep 16-17, 2010, Oslo, Norway
- Bioprocess International: Sep 20-24, 2010, Providence, RI, US
- BIO Japan: Sep 29-Oct 1, 2010, Yokohama, Japan
- AntibOZ-4 International Forum: Sep 30-Oct 4, 2010, Dunk Island, North Queensland, Australia
- Barcelona BioMed Conferences "Macrophages and Iinflammation": Oct 25-27, 2010, Barcelona, Spain
- BIO Europe: Nov 15-17, 2010, Munich, Germany

Our Pipeline

BioInvent develops antibody-based drugs to tackle conditions where there is a significant need for new treatments. We currently have four antibody therapeutics in development. Find out more »

 

 

 

 

 

Clinical Trials

BioInvent is currently running a number of early-stage clinical trials with several of its products. Click here to find out more »